Afatinib Standard Usage and Recommended Daily Dosage

Afatinib is a second-generation EGFR tyrosine kinase inhibitor (TKI) that is commonly used to treat patients with non-small cell lung cancer (NSCLC) carrying EGFR sensitive mutations. The drug has been approved in many countries and regions and has been included in treatment guidelines. In actual clinical use, the usage and recommended dose of afatinib need to be reasonably adjusted according to individual patient conditions to achieve optimal efficacy and control side effects.

The standard recommended dose is 40 mg once daily, orally. Patients should try to take the medicine at the same time every day. Taking it on an empty stomach is more effective. It is best to take it at least 1 hour before a meal or 2 hours after a meal to ensure drug absorption. 40 mg is the initial recommended clinical dose, which is accepted by most patients and can achieve better tumor control effects.

If the patient experiences adverse reactions, the dose can be adjusted. Common adverse reactions of afatinib include diarrhea, rash, stomatitis, etc. If the side effects are severe (such as grade 3 diarrhea or persistent skin reaction), the doctor may recommend reducing the dose to 30 mg, and further reducing it to 20 mg if necessary. Dose adjustment should be based on patient tolerance rather than weakening of tumor control effect. It is not recommended to discontinue or reduce medication on your own, and professional guidance should be followed.

Medication for special populations needs to be carefully evaluated. For patients who are elderly, frail, or have renal or hepatic impairment, a thorough evaluation should be performed before starting treatment. Although patients with mild hepatic and renal impairment usually do not need to adjust the starting dose, patients with moderate to severe impairment need to closely monitor plasma concentrations and adverse reactions when using afatinib. In addition, the safety and effectiveness of afatinib in children have not been established and its use in children or adolescents is not recommended.

Combined medication and patient compliance are important factors affecting efficacy. It is not recommended to take afatinib together with potent CYP450 enzyme inducers, and it should be avoided to take it with drugs that may stimulate gastric acid secretion or affect intestinal absorption. During the treatment process, patients should strictly abide by the daily medication time and dosage schedule, and do not miss or take more than one dose. If you miss a dose due to special reasons, you should take it as soon as possible within 12 hours. If it exceeds that time, skip the dose. Do not double the dose as a remedy.

References：https://www.giotrif.com/